{
    "organizations": [],
    "uuid": "66af0ba935815543dd4da507a223194508b4a4b5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-and-pharmasc/brief-cosmo-pharmaceuticals-and-pharmascience-establish-license-and-supply-agreement-idUSFWN1PQ1JC",
    "ord_in_thread": 0,
    "title": "BRIEF-Cosmo Pharmaceuticals And Pharmascience Establish License And Supply Agreement‍​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - COSMO PHARMACEUTICALS NV:‍​\n* COSMO PHARMACEUTICALS AND PHARMASCIENCE ESTABLISH LICENSE AND SUPPLY AGREEMENT FOR ELEVIEW, METHYLENE BLUE MMX, RIFAMYCIN MMX AND QOLOTAG FOR CANADA​\n* ‍AGREEMENT ENTAILS AN UP-FRONT PAYMENT TO COSMO OF TOTAL CA$ 5 MILLION​\n* ‍ADDITIONAL COMMERCIAL MILESTONE PAYMENTS UPON REACHING CERTAIN ANNUAL SALES THRESHOLDS, AND HIGH DOUBLE-DIGIT ROYALTIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-01T14:05:00.000+02:00",
    "crawled": "2018-02-02T12:45:22.040+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "cosmo",
        "pharmaceutical",
        "nv",
        "cosmo",
        "pharmaceutical",
        "pharmascience",
        "establish",
        "license",
        "supply",
        "agreement",
        "eleview",
        "methylene",
        "blue",
        "mmx",
        "rifamycin",
        "mmx",
        "qolotag",
        "entail",
        "payment",
        "cosmo",
        "total",
        "ca",
        "commercial",
        "milestone",
        "payment",
        "upon",
        "reaching",
        "certain",
        "annual",
        "sale",
        "threshold",
        "high",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}